639090-53-2

Basic information

• Product Name: Cyclopropanecarboxylic acid [4-(4,6-dichloropyrimidin-2-ylsulfanyl)phenyl]amide
• Synonyms: Cyclopropanecarboxylic acid [4-(4,6-dichloropyrimidin-2-ylsulfanyl)phenyl]amide;N-(4-(4,6-dichloropyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide;N-[4-[(4,6-Dichloro-2-pyrimidinyl)thio]phenyl]cyclopropanecarboxamide;N-{4-[(4,6-dichloropyriMidin-2-yl)sulfanyl]phenyl}cyclopropanecarboxaMide;cyclopropane carboxylic acid [4-(4,6-dichloro-pyriMidin-2-ylsulphanyl)-phenyI]-aMide
• CAS NO: 639090-53-2
• Molecular Formula: C₁₄H₁₁Cl₂N₃OS
• Molecular Weight: 340.23
• Product Categories: API intermediates
• Mol File: 639090-53-2.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• Density: 1.52
• Refractive Index: 1.684
• CAS DataBase Reference: Cyclopropanecarboxylic acid [4-(4,6-dichloropyrimidin-2-ylsulfanyl)phenyl]amide(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopropanecarboxylic acid [4-(4,6-dichloropyrimidin-2-ylsulfanyl)phenyl]amide(639090-53-2)
• EPA Substance Registry System: Cyclopropanecarboxylic acid [4-(4,6-dichloropyrimidin-2-ylsulfanyl)phenyl]amide(639090-53-2)

Safety Data

• Hazardous Substances Data: 639090-53-2(Hazardous Substances Data)

Usage

General Description

Cyclopropanecarboxylic acid [4-(4,6-dichloropyrimidin-2-ylsulfanyl)phenyl]amide is a chemical compound with potential biological and pharmaceutical applications. It is a derivative of cyclopropanecarboxylic acid and contains a phenyl amide group attached to a dichloropyrimidine moiety. Cyclopropanecarboxylic acid [4-(4,6-dichloropyrimidin-2-ylsulfanyl)phenyl]amide has demonstrated inhibitory activity against certain enzymes and has shown potential as a pharmaceutical agent in the treatment of certain diseases. Further research and development of this compound may lead to its eventual use as a therapeutic agent in medicine.

InChI:InChI=1/C14H11Cl2N3OS/c15-11-7-12(16)19-14(18-11)21-10-5-3-9(4-6-10)17-13(20)8-1-2-8/h3-8H,1-2H2,(H,17,20)

Upstream product

• 1193-02-8 4-aminotiophenol 
• 639090-54-3 (N-(4-mercaptophenyl)cyclopropylcarboxamide) 
• 4489-34-3 4,6-dichloro-2-(methylsulfonyl)pyrimidine 

Downstream Products

• 639090-55-4 N-[4-({4-chloro-6-[(3-methyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}sulfanyl)phenyl]cyclopropane carboxamide 
• 1079394-26-5 N-(4-(4-(1,2,4-thiadiazol-5-ylamino)-6-chloropyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide 
• 1079394-27-6 N-(4-(4-chloro-6-(pyridin-2-ylamino)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide 
• 1170188-57-4 N-(4-(4-(2-aminoethylamino)-6-(3-methyl-1H-pyrazol-5-ylamino)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide 
• 1450754-47-8 N-(4-(4-(2-(3-(but-3-ynyl)-3H-diazirin-3-yl)ethylamino)-6-(3-methyl-1H-pyrazol-5-ylamino)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide 
• 1079394-17-4 N-(4-(4-(1,2,4-thiadiazol-5-ylamino)-6-(3-cyclopropyl-3-fluoroazetidin-1-yl)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide 
• 1079394-18-5 N-(4-(4-(3-cyclopropyl-3-fluoroazetidin-1-yl)-6-(pyridin-2-ylamino)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide 
• 639090-55-4 N-(4-((4-chloro-6-((5-methyl-1H-pyrazol-3-yl)amino)pyrimidin-2-yl)thio)phenyl)cyclopropanecarboxamide 

Relevant articles and documents

PYRIMIDINE DERIVATIVES AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS

The present invention relates to novel TrkA inhibitors ofofmrula (1) which are useful in the treatment or prevention of acute and chronic pain but also for other abnormal activities of TrkA beyond pain therapy, such as inflammation and cancer.

Tozasertib Analogues as Inhibitors of Necroptotic Cell Death

Receptor interacting protein kinase 1 (RIPK1) plays a crucial role in tumor necrosis factor (TNF)-induced necroptosis, suggesting that this pathway might be druggable. Most inhibitors of RIPK1 are classified as either type II or type III kinase inhibitors. This opened up some interesting perspectives for the discovery of novel inhibitors that target the active site of RIPK1. Tozasertib, a type I pan-aurora kinase (AurK) inhibitor, was found to show a very high affinity for RIPK1. Because tozasertib presents the typical structural elements of a type I kinase inhibitor, the development of structural analogues of tozasertib is a good starting point for identifying novel type I RIPK1 inhibitors. In this paper, we identified interesting inhibitors of mTNF-induced necroptosis with no significant effect on AurK A and B, resulting in no nuclear abnormalities as is the case for tozasertib. Compounds 71 and 72 outperformed tozasertib in an in vivo TNF-induced systemic inflammatory response syndrome (SIRS) mouse model.

Design and synthesis of minimalist terminal alkyne-containing diazirine photo-crosslinkers and their incorporation into kinase inhibitors for cell- and tissue-based proteome profiling

Less is more: A minimalist "clickable" photo-crosslinker (see scheme) was incorporated with numerous small-molecule kinase inhibitors. The resulting probes were used for both in vitro (cell lysates) and in situ (live cells) proteome profiling, for large-scale identification of their potential cellular kinase targets and shows improved outcomes over previous probes. Copyright